Treatment with CRYSVITA® restores phosphate homeostasis in adults and children with XLH leading to clinically meaningful improvements¹⁻⁶
As of 10 September 2021, CRYSVITA® has been approved by Therapeutic Goods Administration (TGA) for the treatment of X-linked hypophosphataemia (XLH) in adults, adolescents and children 1 year of age or older.8
As of 1 November 2022, CRYSVITA® has been listed on the Pharmaceutical Benefits Scheme.
PBS Information: This product is listed on the PBS as a Section 100 item. Refer to the PBS Schedule for full authority information.
CRYSVITA® demonstrates rapid and significant improvements in biochemical and clinical outcomes in children with XLH1,3*
CRYSVITA® significantly improved rickets healing and reduced severity1,3
CRYSVITA® significantly improved growth and mobility outcomes1,3
CRYSVITA® significantly improved biochemical markers of phosphate regulation and bone health1,3
*Based on a Phase 2 and a Phase 3 study. In the Phase 2 study, 52 children with XLH aged 5–12 years were randomised to receive CRYSVITA® either every 2 weeks or every 4 weeks (dose was titrated according to serum phosphorus concentration). In the Phase 3 study, 61 children with XLH aged 1–12 years were randomised to receive either CRYSVITA® (0.8 mg/kg starting dose, administered every 2 weeks) or conventional therapy (oral phosphate and Vitamin D). In both studies, change in rickets was assessed at 40 weeks.
CRYSVITA® restores phosphate homeostasis in adults with XLH by targeting the underlying pathophysiology4,5
CRYSVITA® improves stiffness, functional disability and pain in adults with XLH4,5
CRYSVITA® is associated with greater healing of pseudofractures/fractures in adults with XLH6
CRYSVITA® is given as a subcutaneous injection every 4 weeks in adults7
CRYSVITA® treatment was well tolerated and had an acceptable safety profile in adults with XLH4,5
1. Carpenter TO, et al. N Engl J Med. 2018;378:1987–98. 2. Whyte MP, et al. Lancet Diabetes Endocrinol 2019;7:189–99. 3. Imel EA,et al. Lancet. 2019;393:2416–27. 4. Insogna KL, et al J Bone Miner Res. 2018;33:1383-9. 5. Portale AA, et al. Calcif Tissue Int. 2019;105:271-84. 6. Insogna KL, et al. J Bone Miner Res. 2019;34:2183-91. 7. Lamb YN. Drugs. 2018;78(6):707–14. 8. Australian Product Information for Crysvita® (burosumab) approved 10 September 2021. https://www.kyowakirin.com/australia/our_medicines/doc/crysvita_product_information_leaflet.pdf. Last updated: Sept 2021 Last accessed: March 2023.
